Physician profile
Nhat C Vo
NPI 1215924451
$3,515.84
in general payments reported to CMS, 2019-2025
28 companies · $656 in 2025
The $656 reported for 2025 was more than what 96% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $435 · 2021: $784 · 2022: $437 · 2023: $659 · 2024: $433 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,748.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $844.33 | 2019-2025 | Repatha, Evenity, Otezla |
| Abbvie INC. | $619.88 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $455.36 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $226.31 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $176.34 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $168.03 | 2019-2025 | |
| Novo Nordisk INC | $148.62 | 2020-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $143.91 | 2020-2025 | Airsupra |
| Idorsia Pharmaceuticals US INC | $108.11 | 2022-2023 | Quviviq |
| Alk-Abello, INC | $63.83 | 2023-2025 | Odactra, Ragwitek, Grastek |
| Bayer Healthcare Pharmaceuticals INC. | $61.56 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.62 | 2020-2023 | Jardiance |
| Vanda Pharmaceuticals INC. | $52.85 | 2025 | Fanapt |
| Ars Pharmaceuticals Operations, INC. | $49.63 | 2025 | Neffy |
| Allergan, INC. | $47.48 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $42.25 | 2021-2022 | |
| Amarin Pharma, INC. | $36.34 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $33.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $33.84 | 2019 | |
| Genentech USA, INC. | $27.39 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $24.04 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $19.90 | 2025 | Zoryve |
| Otsuka America Pharmaceutical, INC. | $18.93 | 2022 | |
| Exact Sciences Corporation | $14.16 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $12.50 | 2021 | |
| Merck Sharp & Dohme LLC | $11.78 | 2020 | |
| Metacel Pharmaceuticals LLC | $11.49 | 2023 | Ozobax |
| Team_makena_llc | $5.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nhat Vo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.